PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Alnylam Pharmaceuticals, Inc. (ALNY)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS02043Q1076
CUSIP02043Q107
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$18.69B
EPS-$2.64
PEG Ratio-0.49
Revenue (TTM)$2.00B
Gross Profit (TTM)$868.60M
EBITDA (TTM)-$122.30M
Year Range$141.98 - $218.88
Target Price$222.68
Short %2.39%
Short Ratio5.37

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Alnylam Pharmaceuticals, Inc.

Popular comparisons: ALNY vs. SPY, ALNY vs. VOO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Alnylam Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


500.00%1,000.00%1,500.00%2,000.00%2,500.00%3,000.00%December2024FebruaryMarchAprilMay
2,396.84%
373.47%
ALNY (Alnylam Pharmaceuticals, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Alnylam Pharmaceuticals, Inc. had a return of -21.60% year-to-date (YTD) and -20.29% in the last 12 months. Over the past 10 years, Alnylam Pharmaceuticals, Inc. had an annualized return of 9.76%, while the S&P 500 had an annualized return of 10.70%, indicating that Alnylam Pharmaceuticals, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-21.60%11.24%
1 month4.71%4.04%
6 months-7.00%16.49%
1 year-20.29%26.17%
5 years (annualized)16.97%13.76%
10 years (annualized)9.76%10.70%

Monthly Returns

The table below presents the monthly returns of ALNY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-9.67%-12.62%-1.09%-3.68%-21.60%
2023-4.73%-15.44%4.63%-0.56%-7.12%2.66%2.87%1.24%-10.47%-14.29%10.84%13.77%-19.46%
2022-18.86%14.72%3.45%-18.29%-5.72%15.94%-2.61%45.50%-3.15%3.55%6.43%7.73%40.14%
202115.78%-1.58%-4.67%-0.39%0.96%19.39%5.56%12.57%-6.27%-15.49%15.19%-7.74%30.48%
2020-0.33%2.50%-7.49%20.99%2.71%9.49%-1.59%-9.00%9.77%-15.54%5.64%0.05%12.85%
201914.57%1.76%9.94%-4.40%-24.42%7.46%6.93%4.00%-0.33%7.86%35.05%-1.68%57.96%
20182.31%-7.56%-0.88%-20.63%5.23%-0.99%-3.54%29.13%-28.65%-8.10%0.91%-10.17%-42.61%
20176.81%29.13%-0.76%4.59%22.13%21.85%3.74%3.61%37.05%3.70%10.42%-5.57%239.34%
2016-26.77%-15.04%7.17%6.80%6.98%-22.63%22.69%2.60%-2.96%-47.48%23.23%-14.66%-60.23%
2015-3.27%8.21%2.85%-2.44%28.68%-8.56%6.31%-19.24%-21.91%6.96%21.07%-9.53%-2.95%
201430.11%-2.89%-17.36%-26.23%19.71%6.54%-14.33%28.74%12.10%18.75%8.42%-3.53%50.86%
201332.22%-1.82%2.87%-1.72%27.89%1.21%48.94%12.19%23.57%-10.00%6.23%5.07%252.33%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ALNY is 18, indicating that it is in the bottom 18% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of ALNY is 1818
ALNY (Alnylam Pharmaceuticals, Inc.)
The Sharpe Ratio Rank of ALNY is 1717Sharpe Ratio Rank
The Sortino Ratio Rank of ALNY is 1717Sortino Ratio Rank
The Omega Ratio Rank of ALNY is 1818Omega Ratio Rank
The Calmar Ratio Rank of ALNY is 1818Calmar Ratio Rank
The Martin Ratio Rank of ALNY is 2222Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Alnylam Pharmaceuticals, Inc. (ALNY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ALNY
Sharpe ratio
The chart of Sharpe ratio for ALNY, currently valued at -0.59, compared to the broader market-2.00-1.000.001.002.003.004.00-0.59
Sortino ratio
The chart of Sortino ratio for ALNY, currently valued at -0.65, compared to the broader market-4.00-2.000.002.004.006.00-0.65
Omega ratio
The chart of Omega ratio for ALNY, currently valued at 0.92, compared to the broader market0.501.001.502.000.92
Calmar ratio
The chart of Calmar ratio for ALNY, currently valued at -0.47, compared to the broader market0.002.004.006.00-0.47
Martin ratio
The chart of Martin ratio for ALNY, currently valued at -0.97, compared to the broader market-10.000.0010.0020.0030.00-0.97
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.43, compared to the broader market-2.00-1.000.001.002.003.004.002.43
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.44, compared to the broader market-4.00-2.000.002.004.006.003.44
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.43, compared to the broader market0.501.001.502.001.43
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.96, compared to the broader market0.002.004.006.001.96
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 9.23, compared to the broader market-10.000.0010.0020.0030.009.23

Sharpe Ratio

The current Alnylam Pharmaceuticals, Inc. Sharpe ratio is -0.59. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Alnylam Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2024FebruaryMarchAprilMay
-0.59
2.43
ALNY (Alnylam Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Alnylam Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-40.00%-30.00%-20.00%-10.00%0.00%December2024FebruaryMarchAprilMay
-37.81%
-0.29%
ALNY (Alnylam Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alnylam Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alnylam Pharmaceuticals, Inc. was 83.58%, occurring on Oct 3, 2011. Recovery took 439 trading sessions.

The current Alnylam Pharmaceuticals, Inc. drawdown is 37.81%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-83.58%Oct 10, 20071004Oct 3, 2011439Jul 3, 20131443
-77.36%Jun 23, 2015347Nov 3, 2016257Nov 10, 2017604
-57.81%Mar 21, 2018193Dec 24, 2018374Jun 19, 2020567
-52.18%Jun 10, 200446Aug 16, 2004100Jan 6, 2005146
-47.61%Jan 14, 201472Apr 28, 2014126Oct 24, 2014198

Volatility

Volatility Chart

The current Alnylam Pharmaceuticals, Inc. volatility is 7.52%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%December2024FebruaryMarchAprilMay
7.52%
3.00%
ALNY (Alnylam Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alnylam Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items